Dramatic response to alectinib in a patient with ALK ‐rearranged squamous cell lung cancer-Reference-Cited by-同舟云学术

Dramatic response to alectinib in a patient with ALK ‐rearranged squamous cell lung cancer

Published:2021-07-29 Issue:17 Volume:12 Page:2420-2423
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Shiihara Jun¹,Ohyanagi Fumiyoshi¹²,Amari Hikari¹,Toda Minemichi¹,Tahara Hiroki¹,Yuzawa Motoi¹,Maeda Yuki¹,Nomura Motoko¹,Mizushina Yoshiko¹³,Nagai Yoshiaki¹,Ohta Hiromitsu¹,Yamaguchi Yasuhiro¹

Affiliation:

1. Division of Respiratory Medicine, Clinical Department of Internal Medicine Jichi Medical University Saitama Medical Center Saitama Japan

2. Division of Respiratory Medicine, Saitama Cancer Center Saitama Japan

3. Division of Pulmonary Medicine, Department of Medicine Jichi Medical University Tochigi Japan

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.14092

Reference17 articles.

1. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology

2. Cancer statistics, 2014

3. Squamous Cell Carcinoma of the Lung: Molecular Subtypes and Therapeutic Opportunities

4. Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

5. Pathology of Lung Cancer

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy analysis of ALK inhibitors for treating lung squamous carcinoma patients harboring ALK rearrangement;Journal of Thoracic Disease;2024-07

2. Frequency and functional characterization of fusion genes in squamous cell carcinoma of the lung;Gene;2024-02

3. EML4-ALK fusions drive lung adeno-to-squamous transition through JAK-STAT activation;Journal of Experimental Medicine;2024-01-29

4. The safety and efficacy for the treatment of alectinib in a women with ALK-positive lung cancer delivered a healthy male neonate throughout Pregnancy: A case report;Lung Cancer;2023-06